Severe Malaria and Anti-malarial Drug Resistance in Cambodia
Severe Malaria and Anti-malarial Drug Resistance in Cambodia
This study, conducted by the National Center for Malaria Control of Cambodia's Ministry of
 Health, the Guangzhou University of Traditional Chinese Medicine in the People's Republic of
 China, and the U.S. National Institutes of Health, will explore why some people with mild
 malaria progress to a severe form of the disease and why some malaria parasites are resistant
 to treatment.

 Malaria is caused by a parasite that is transmitted to humans through a mosquito bite. It can
 cause fever, aches, and weakness. Left untreated, it can cause severe illness and even death.
 Malaria can be cured when it is treated with effective medicine, but some malaria parasites
 are resistant to medicine.

 Children and adults with malaria symptoms and parasites in their blood will be recruited for
 this study from the Pursat Regional Health Center in Cambodia and the Thai-Cambodian border
 area within Pursat Province.

 Participants are hospitalized for 4 to 6 days at the Pursat Regional Health Center. A small
 blood sample is collected for genetic study and to look for substances in the blood, such as
 certain proteins, that may help protect against severe malaria. Patients are then treated
 with two doses of Artequick(Registered Trademark) (artemisinin-piperaquine), the first dose
 upon arrival at the hospital and the second the next day. (Participants who are pregnant will
 be treated with either quinine or artesunate-mefloquine instead of Artequick.)

 Patients undergo fingersticks several times during their hospital stay to collect a small
 drop of blood to monitor parasite counts. They are discharged from the hospital when their
 symptoms resolve and parasites can no longer be detected in their blood. After discharge,
 patients return to the clinic once a week for 3 weeks for a blood test to monitor for
 parasites, as some parasites may be slightly resistant to the medication. Patients in whom
 symptoms or parasites reappear undergo treatment with artesunate and mefloquine.

 ...
Hemoglobin E (HbE) is distinguished from normal HbA by a single amino acid mutation (beta26:
 Glu to Lys). High allele frequencies in some areas of Cambodia are believed to have been
 naturally selected by life-threatening manifestations of malaria. Few epidemiological studies
 support this hypothesis, however, and in vitro studies have not clearly defined a mechanism
 of protection. The prevalence of drug-resistant malaria is alarmingly high along the
 Thai-Cambodian border, such that chloroquine, quinine, or mefloquine can no longer effect
 acceptable cure rates. Recently, prolonged parasite clearance times after artemisinin
 treatment have been documented in Battambang and Pailin provinces in Cambodia. Combinations
 of artemisinins and other drugs (e.g., mefioquine, piperaquine) are now used as standard
 first-line treatments for P. falciparum malaria in Southeast Asia. Further decreases in the
 effectiveness of these drugs would constitute a disaster, making some cases of malaria
 essentially untreatable. The molecular basis for parasite resistance to these antimalarials
 has not been firmly established. The main aims of this study are to (1) determine whether HbE
 protects against severe P. falciparum malaria, (2) identify genetic determinants associated
 with parasite resistance to antimalarial drugs, and (3) determine whether HbE and other
 erythrocyte polymorphisms influence parasite clearance times after artemisinin treatment. To
 meet these aims, we are conducting an unmatched case-control study comparing the prevalence
 of HbE in patients with severe and uncomplicated P. falciparum malaria. Cambodians who
 complain of fever and/or symptoms of malaria are recruited from Pursat Regional Health Center
 and surrounding districts within Pursat Province. Patients with uncomplicated malaria are
 treated with weight-based doses of artesunate given orally each day for 3 days, followed by
 weight-based doses of mefloquine given orally each day for 2 days. Patients with severe
 malaria will be treated with artemisinin compounds given parenterally for 5 consecutive days,
 followed by artesunate plus mefioquine treatment, as above. We will also collect parasitized
 blood samples from malaria patients prior to antimalarial drug administration. These
 parasites will be tested in short-term in vitro culture experiments to determine their
 susceptibility to antimalarial drugs. Genome-wide typing of drug-sensitive and drug-resistant
 P. falciparum isolates (using microsatellite and single nucleotide polymorphism markers) and
 genetic association studies will be used to identify genes that determine parasite responses
 to various antimalarial drugs.
-  INCLUSION CRITERIA:

 Uncompleted malaria: Age greater than 10 years axillary, temperature greater than 37.5
 degrees Celsius or history of fever, signs and symptoms of malaria (e.g. headache, body
 aches, malaise), asexual parasitemia greater than or equal to 10000/ul, NO criteria of
 severe malaria and NO other etiologies of febrile illness (e.g., respiratory tract
 infection) on clinical examination, and NO history of antimalarial drug use for present
 symptoms.

 Severe malaria: Age greater than or equal to 10 years, asexual parasitemia greater than or
 equal to 10000/uL, NO history of antimalarial drug use for present symptoms, and any one of
 the following: coma (defined as Glasgow coma score less than or equal to 9 in adults, or
 Blantyre coma score less than or equal to 2 in children), convulsions (witnessed),
 prostration, severe anemia (hemoglobin less than 5 g/dL), respiratory distress,
 hypoglycemia (serum glucose less than 40 mg/dL), jaundice/icetrus, renal insufficiency
 (anuria for 24 hours or more), hemoglobinuria, state of shock (systolic blood pressure less
 than 50 mmHg, rapid pulse, cool extremities), cessation of eating and drinking, repetitive
 vomiting.

 EXCLUSION CRITERIA:

 Individuals who live in malaria endemic areas and are asymptomatic or have anon-malaria
 illness can sometimes be incidentally noted to be parasitemic, patients who are parasitemic
 yet are found by clinical examination to have another etiology of febrile illness (e.g.
 respiratory tract infection) will be excluded from the protocol, but will be treated by the
 Cambodian Ministry of Health staff for both malaria and their coexisting infection.
 Pregnant women will also be excluded from this protocol but will be treated by study
 physicians with guinine (first trimester) or artemisinin-mefloquine (second or third
 trimester).